Ela Borenstein
Direktor/Vorstandsmitglied bei Alethia Biotherapeutics, Inc.
Profil
Ela Borenstein is currently the Director at Alethia Biotherapeutics, Inc. and the Vice President at BDC Venture Capital.
Previously, she held positions as Director at Cytochroma, Inc., Milestone Pharmaceuticals, Inc., Trillium Therapeutics, Inc., and EastMed, Inc. She also served as Director at Allostera Pharma, Inc. from 2009 to 2013.
Additionally, Ms. Borenstein has experience as Vice President-Clinical & Regulatory Affairs at Theratechnologies, Inc. and Senior Vice President-Scientific Affairs at Technilab Pharma.
She was also the VP-Regulatory Affairs & Product Strategy at CelMed BioSciences, Inc. Ms. Borenstein obtained a graduate degree from the University of Toronto, an undergraduate degree from the University of Western Ontario, and an MBA from Université du Québec à Montréal.
Aktive Positionen von Ela Borenstein
Unternehmen | Position | Beginn |
---|---|---|
BDC Venture Capital
BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Private Equity Investor | - |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | 20.07.2009 |
Ehemalige bekannte Positionen von Ela Borenstein
Unternehmen | Position | Ende |
---|---|---|
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Direktor/Vorstandsmitglied | 06.06.2014 |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Direktor/Vorstandsmitglied | 09.09.2013 |
THERATECHNOLOGIES INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
MILESTONE PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | - |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | Direktor/Vorstandsmitglied | - |
Ausbildung von Ela Borenstein
University of Western Ontario | Undergraduate Degree |
University of Toronto | Graduate Degree |
Université du Québec à Montréal | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MILESTONE PHARMACEUTICALS INC. | Health Technology |
THERATECHNOLOGIES INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
BDC Venture Capital
BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Finance |
EastMed, Inc.
EastMed, Inc. Medical SpecialtiesHealth Technology EastMed, Inc. designs, manufactures and distributes medical device for women's health and wellness. It develops uresta, a female continence care kit that is designed to stop bladder leakage and empower women to manage their stress urinary incontinence. The company was founded by Scott Farrell in 2002 and is headquartered in Dartmouth, Canada. | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
CelMed BioSciences, Inc.
CelMed BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Celmed BioSciences Inc. is a biopharmaceutical company. The company is engaged in developing breakthrough products to treat cancer. The company offers rational drug design and pharmacogenomic concepts to improve cancer patient care. Products of the company include Theralux and NB1011 which offers “Trojan horse solution' to treat cancer. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
Technilab Pharma | Health Technology |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | Health Technology |